Schering-Plough Corporation today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug. Temozolomide is marketed as TEMODAL in the EU and as TEMODAR in the US.
The details can be read here.
No comments:
Post a Comment